RE:RE:RE:RE:RE:RE:RE:RE:RE:TH1902 ClinicalTrials.gov Update ????
It's becoming a little "pathetic", isn't it????!!
How many years have Pharma -big and mid size- had the time to partner or buy TH????
And now that oncology failed in their phase 1 and the Chinese partner (was there one...???) for Nash walked away??? , you think a BO can happen???!!!
Really, man, how low can you fall???
Many, many many other "biotechs" with much more credits at low prices that can be bought!!!!
Wish you good luck with those millions of shares!
PS: wonders happen sometimes
SPCEO1 - (1/30/2023 12:43:24 PM)
RE:RE:RE:RE:RE:RE:RE:RE:TH1902 ClinicalTrials.gov Update
THTX has some impressive tax loss carryforwards, so anyone wanting to access them might be interested, particulalrly if they have another good reason to buy THTX. One of those reasons might be NASH since Egrifta would seem to have a very good shot at helping patients with NASH. Cancer may also intrigue another company expecially if it is fairly obvious that a different approach might generate better results.I doubt the legacy drugs interest anyone with the possible expection of Taimed who might want to take over the marketing of Trogarzo and start building a US marketing base for when their next HIV drug hits the market. There are plenty of options for potential buyers from large pharma companies to more mid-sized ones and then there are financial buyers too. That being said, an acquisition still seems unlikely to me.
Joemare wrote:Thera fatigue. Well said. Have the current executives and board reached capacity? Are they at a know-how fatigue? Who would buy this company??